TY -的T1 -十二指肠注入左旋多巴单一疗法与口服复方用药在神经学先进的帕金森病JF -神经学乔- SP - 216 LP - 223 - 10.1212/01. wnl.0000149637.70961.4c六世- 首页64 - 2非盟- d . Nyholm盟a .贝聿铭尼尔森Remahl AU - n . Dizdar AU - r . Constantinescu盟- b Holmberg简颂盟盟- r - s - m。Aquilonius AU - h . Askmark Y1 - 2005/01/25 UR - http://n首页.neurology.org/content/64/2/216.abstract N2 -目的:比较白天intraduodenal左旋多巴/卡比多巴输液作为单一疗法与单独优化传统的联合疗法在晚期帕金森病(PD)患者运动波动和生活质量(QoL)。方法:24例与运动波动和运动障碍进行了研究在随机交叉设计比较个性化的常规治疗和intraduodenal注入左旋多巴/卡比多巴凝胶为3 + 3周。视频得分的运动机能被盲法评估评估全球治疗反应规模从−3 - 0到+ 3(从严重的“上”“下”“on”有严重运动障碍)。病人自我评估电机性能和生命质量是通过使用一个电子日记。结果:中位数百分比的评级功能”对“区间(−1 + 1)从81年的100%增加了输液治疗(p & lt;0.01)。这个进步是伴随着减少“关闭”状态(p & lt;0.01)运动障碍,也没有增加。中位数统一帕金森病评定量表得分下降从53到35的输液(p & lt; 0.05). QoL was improved, using the two instruments: Parkinson's Disease Questionnaire-39 and 15D Quality of Life Instrument (p < 0.01). Adverse events were similar for both treatment strategies. Conclusions: Continuous intraduodenal infusion of the levodopa/carbidopa enteral gel as monotherapy is safe and clinically superior to a number of individually optimized combinations of conventional oral and subcutaneous medications in patients with motor fluctuations. Intraduodenal infusion of levodopa offers an important alternative in treating patients with advanced Parkinson disease. ER -